Glucagon stimulation test for estimating endogenous insulin secretion in dogs

Area of Science:

• Veterinary Medicine
• Endocrinology
• Canine Health

Background:

• Canine diabetes mellitus is a common endocrine disorder.
• Assessing residual pancreatic beta-cell function is crucial for understanding disease progression and recovery.
• C-peptide levels serve as a marker for endogenous insulin production.

Purpose of the Study:

• To evaluate the effect of glucagon stimulation on C-peptide, insulin, and glucose concentrations in dogs.
• To compare C-peptide responses in healthy, diabetic, and recovered diabetic dogs.
• To assess the utility of glucagon as a diagnostic tool in canine diabetes.

Main Methods:

• Fifty-one dogs (27 diabetic, 4 recovered, 20 healthy) received intravenous glucagon (0.5 or 1.0 mg).
• Blood samples were collected pre-injection and at 10 and 20 minutes post-injection.
• Serum C-peptide, insulin, glucose, and fructosamine levels were analyzed.

Main Results:

• Median C-peptide concentrations at 10 minutes post-glucagon were significantly lower in diabetic dogs (0.1 nmol/l) compared to controls (0.5 nmol/l) and recovered dogs (0.3 nmol/l).
• Diabetic dogs exhibited impaired C-peptide response to glucagon stimulation.
• Mild adverse reactions were observed in 7 out of 51 dogs.

Conclusions:

• Glucagon stimulation test can differentiate between diabetic and healthy dogs based on C-peptide response.
• Lower C-peptide levels in diabetic dogs confirm reduced endogenous insulin secretion.
• The study highlights potential for assessing pancreatic function in canine diabetes.